CHICAGO--(BUSINESS WIRE)--Celsis In Vitro Technologies Inc. (Celsis IVT), a division of the global life sciences company Celsis International plc, today announced the availability of Celsis InVitroCYP microsomes for pre-clinical research. As the first microsome product line formulated to deliver different classifications of cytochrome P450 (CYP) enzyme activity—high levels for inhibitions studies (InVitroCYP H-class), moderate levels for metabolic studies (InVitroCYP M-class) and custom activity levels (InVitroCYP C-class)—Celsis InVitroCYPs now enable researchers to choose a microsome product to optimize their specific study outcomes.